1 week Ago By Defense World Staff
JPMorgan Chase & Co. grew its holdings in shares of Krystal Biotech, Inc. ( NASDAQ:KRYS – Free Report ) by 18.
7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 151,835 shares of the company’s stock after acquiring an additional 23,934 shares during the period. JPMorgan Chase & Co.
owned about 0.53% of Krystal Biotech worth $23,786,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Several other hedge funds and other institutional investors also recently added to or reduced their stakes in KRYS.
State Street Corp boosted its holdings in shares of Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares during the last quarter.
Raymond James Financial Inc. purchased a new stake in shares of Krystal Biotech in the fourth quarter worth approximately $15,989,000. Franklin Resources Inc.
boosted its stake in shares of Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc.
now owns 243,760 shares of the company’s stock valued at $43,774,000 after purchasing an additional 62,178 shares during the period. TimesSquare Capital Management LLC grew its stake in Krystal Biotech by 39.1% in the 4th quarter.
TimesSquare Capital Management LLC now owns 158,868 shares of the company’s stock worth $24,888,000 after acquiring an additional 44,646 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Krystal Biotech by 1.
0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock worth $450,938,000 after purchasing an additional 28,707 shares during the period.
86.29% of the stock is owned by hedge funds and other institutional investors. Analyst Ratings Changes A number of brokerages have commented on KRYS.
Citigroup boosted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th.
Jefferies Financial Group assumed coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a “buy” rating and a $245.00 price objective for the company.
Chardan Capital upped their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th.
Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Finally, HC Wainwright reissued a “buy” rating and set a $221.
00 target price on shares of Krystal Biotech in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.
com, Krystal Biotech currently has a consensus rating of “Buy” and a consensus target price of $220.00. Krystal Biotech Trading Up 6.
0 % Shares of KRYS opened at $168.16 on Thursday. The firm has a 50-day moving average price of $173.
85 and a 200 day moving average price of $172.48. Krystal Biotech, Inc.
has a 12-month low of $141.72 and a 12-month high of $219.34.
The firm has a market capitalization of $4.84 billion, a P/E ratio of 56.24 and a beta of 0.
75. Krystal Biotech ( NASDAQ:KRYS – Get Free Report ) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.
52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23.
Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%.
The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million.
During the same quarter in the prior year, the company posted $0.30 EPS. The company’s quarterly revenue was up 116.
4% on a year-over-year basis. Equities research analysts predict that Krystal Biotech, Inc. will post 6.
14 earnings per share for the current fiscal year. Insider Buying and Selling at Krystal Biotech In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.
79, for a total transaction of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.
69. The trade was a 1.68 % decrease in their ownership of the stock.
The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website . Also, CAO Kathryn Romano sold 750 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.
22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.
88. This trade represents a 5.62 % decrease in their position.
The disclosure for this sale can be found here . 14.10% of the stock is owned by corporate insiders.
Krystal Biotech Company Profile ( Free Report ) Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). Featured Articles Five stocks we like better than Krystal Biotech Where to Find Earnings Call Transcripts Quantum Computing: The $6.
5 Billion Opportunity You Can’t Ignore Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index Are Tariffs Threatening Disney’s Comeback Story? 3 Healthcare Dividend Stocks to Buy Is Alphabet a Generational Buying Opportunity at These Levels? Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter ..
